Key Highlights

  • 2.35 is the per-share loss, written as -2.35, implied by the consensus estimate for Inhibrx Biosciences, Inc. (NASDAQ:INBX) ahead of its Q3 2026 release once trading ends on November 13, 2026.
  • 36.7 million is the USD net loss for Q2 of 2026, equal to USD 2.34 per share, against a USD 28.7 million loss and USD 1.85 per share in the year-ago period.
  • 219.5 million is the USD cash position on August 6, 2026, up from USD 133.3 million on June 30 after a USD 100.0 million Loan drawdown on July 15, 2026.
  • 1.33 billion is the USD market Capitalization in the screening data, while the FDA assigned an April 14, 2027 PDUFA goal date to ozekibart, a treatment candidate for conventional chondrosarcoma.

What Canadian Investors Can Expect From Inhibrx Biosciences, Inc. (NASDAQ:INBX) on November 13, 2026

Inhibrx Biosciences, Inc. has scheduled its Q3 2026 results for November 13, 2026, following the market close (AMC). Consensus sits at a loss of 2.35 per share in the screening data, next to USD 1.33 billion of market capitalization. Compare that with the Q2 loss of USD 2.34 per share across roughly 15.7 million weighted shares. Q2 brought no revenue, whereas the year-ago period brought USD 1.3 million.

The Rationale: Latest Quarter and Management Outlook for Inhibrx Biosciences, Inc. (NASDAQ:INBX)

Research and development spending in Q2 was USD 23.9 million against USD 22.3 million, administrative spending was USD 8.3 million against USD 6.4 million, with USD 4.5 million of other expense. The half-year net loss was USD 70.1 million, or USD 4.49 per share. The FDA accepted the BLA for ozekibart in June 2026. Management had lined up INBRX-106 progression-free survival results for third-quarter 2026, an FDA meeting about colorectal cancer in fourth-quarter 2026, and interim colorectal results during first-quarter 2027.

Valuation, Liquidity and Risks for Inhibrx Biosciences, Inc. (NASDAQ:INBX)

The screening data puts Market Value at USD 1.33 billion. Net long-term Debt was USD 176.3 million versus a USD 175.0 million loan balance, while the stockholders' Deficit stood at USD 53.0 million on June 30, 2026. Another USD 225.0 million of loan funding could be offered if the lender chooses. No explicit estimate of cash runway was offered. Risks include trial results, regulator decisions, servicing debt, ongoing losses and reliance on a handful of programs. The INBRX-106 trial result did not turn up in published reporting.

Where Things Stand

Inhibrx Biosciences, Inc. (NASDAQ:INBX) publishes once trading ends on November 13, 2026, with consensus at -2.35 per share and USD 1.33 billion of market value in the screening data. Cash of USD 219.5 million on August 6, 2026 follows a USD 100.0 million loan drawdown, while the Q2 net loss was USD 36.7 million. Ozekibart faces an April 14, 2027 FDA goal date, plus a fourth-quarter FDA meeting about colorectal cancer, along with interim colorectal results due first-quarter 2027. Expect focus on spending, borrowings and trial news. This article is for general information, and it should be read as commentary rather than advice.